Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Daniel J. Tenney, Richard J. Colonno, Carl J. Baldick et al.|Hepatology|2009Cited by 815
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis BMorris Sherman, R. Hindes, Cihan Yurdaydın et al.|Gastroenterology|2006Cited by 414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis BRichard J. Colonno, Daniel J. Tenney, Ronald E. Rose et al.|Hepatology|2006Cited by 348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentDaniel J. Tenney, Richard J. Colonno, Ronald E. Rose et al.|Antimicrobial Agents and Chemotherapy|2006Cited by 239
Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic responseCarl J. Baldick, Richard J. Colonno, Jie Fang et al.|Journal of Hepatology|2008Cited by 68